Two treatment methods for hepatocellular carcinoma:Lenvatinib or bevacizumab combined with sintilimab and interventional therapy  

作　　者：Fei-Yu Zhao Xiao-Ming Zhang Nian-Song Qian 

机构地区：[1]Department of Thoracic Oncology,Respiratory and Critical Care Medicine,The Eighth Medical Center of People’s Liberation Army General Hospital,Beijing 100853,China

出　　处：《World Journal of Gastroenterology》2025年第10期164-167,共4页世界胃肠病学杂志(英文)

摘　　要：In their study,Han et al compared the efficacy of bevacizumab plus sindilizumab plus interventional therapy with that of lenvatinib plus sindilizumab plus interventional therapy for patients with intermediate and advanced hepatocellular carcinoma.The triple therapy,which integrates interventional therapy,targeted therapy,and immunotherapy,has emerged as a promising research focus in the treatment of liver cancer.Consequently,it is of utmost significance to select an appropriate combination of interventional therapy,targeted therapy,and immunotherapy for patients suffering from intermediate and advanced liver cancer.

关 键 词：Hepatocellular carcinoma BEVACIZUMAB Lenvatinib Sintilimab Interventional treatment 

分 类 号：R735.7[医药卫生—肿瘤]